EDISON, N.J.—Carotech is beginning a human clinical trial on tocotrienols, specifically evaluating the neuroprotective and anti-atherogenic properties of Tocomin® SupraBio™—patented and bioenhanced natural full spectrum palm tocotrienol complex.
The three-year randomized, double blind, placebo-controlled study, involving 400 subjects, is funded by the Malaysian Palm Oil Board and the Ministry of Science, Malaysia and soft gels will be provided by Carotech. The phase II clinical trial will evaluate and review white matter changes in the brain using magnetic resonance imaging (MRI) before, during and after supplementation.
Large animal studies conducted by professor Chandan Sen and his group of researchers at The Ohio State University Medical Center showed extremely low levels of Tocomin prevented glutamate-induced death of neuron cells in mice through the inhibition of c-Src kinase and 12-lipoxygenase. In addition, tocotrienol-supplemented rats showed more protection against stroke-induced injury (significant reduction in volume of cerebral infarct) compared with matched controls. The study will also evaluate the effects of tocotrienols on blood parameters such as total lipid profile, Apo-B, C-reactive protein, antioxidant profile, Lp(a) and lipid peroxidation (secondary objectives).
